Andre Goy, MD, discusses the role of rituximab and bendamustine plus cytarabine as a treatment for patients with mantle cell lymphoma.
Andre Goy, MD, chief in the division of lymphoma, chairman and director at John Theurer Cancer Center, discusses the role of rituximab (Rituxan) and bendamustine plus cytarabine (R-BAC) as a treatment for patients with mantle cell lymphoma (MCL).
Goy says the data with R-BAC are interesting because the agents are combined to get the best of both rituximab and bendamustine, with low-dose cytarabine for age and myelotoxicity. Outside of clinical trials, Goy says R-BAC is an appealing option because it offers a sustainable progression-free survival, duration of response, and a very high complete response rate.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More